

Adis Clinical Trials Insight: Presented at Meetings - Antithrombotics

The table below highlights some of the randomised trials presented during sessions at the meetings described.

Annual Scientific Sessions of the American Heart Association (82nd : November 2009 : Orlando, Florida, USA)

Adis CTI Record	Drug(s)	Purpose	Study Results	Sponsor
1 803004013	Clopidogrel Ticagrelor	This study compared the effects of ticagrelor and clopidogrel on cardiopulmonary function in patients with stable coronary artery disease (CAD).	Ticagrelor had no effect on cardiopulmonary function in stable coronary artery disease patients.	AstraZeneca
2 803004107	Clopidogrel Ticagrelor	This study compared the effects of ticagrelor [AstraZeneca] and clopidogrel on platelet reactivity in patients with stable coronary artery disease.	Ticagrelor was associated with a significantly lower prevalence of high on-treatment platelet reactivity to adenosine diphosphate at all timepoints post-dose compared with clopidogrel in patients with stable coronary artery disease.	AstraZeneca
3 803004098	Clopidogrel Ticagrelor	This PLATO substudy compared the inhibition of platelet function in patients with acute coronary syndromes (ACS) receiving maintenance treatment with ticagrelor [AstraZeneca] or clopidogrel for the prevention of cardiovascular disorders.	Ticagrelor achieved greater inhibition of platelet function than standard clopidogrel therapy in patients with acute coronary syndromes receiving maintenance treatment for the prevention of cardiovascular disorders. The maximum light transmittance aggregometry response induced with adenosine diphosphate, and platelet reactivity index values, were significantly lower in ticagrelor than clopidogrel recipients at both trough and peak concentrations (all p<0.001).	AstraZeneca
4 803004131	Clopidogrel Ticagrelor	This study compared the inhibitory effects of ticagrelor [AstraZeneca] and clopidogrel on platelet aggregation in patients with acute coronary syndromes (ACS). In particular, the onset and extent of inhibition of platelet function were assessed.	Ticagrelor 180mg loading dose had a more rapid onset of action and achieved greater inhibition of platelet function than clopidogrel in patients with acute coronary syndromes. Substantial inhibition of platelet aggregation was evident at 1h postdose and sustained until 12h postdose in ticagrelor recipients.	AstraZeneca
5 803003991	Cardiovascular-therapies	This study investigated the cost effectiveness of early revascularisation versus initial medical stabilisation with clinically selected delayed revascularisation in patients with acute myocardial infarction complicated by cardiogenic shock.	Early revascularisation was associated with a discounted incremental cost of \$US30,857 per life-years saved compared with initial medical stabilisation with clinically selected delayed revascularisation in patients with acute myocardial infarction complicated by cardiogenic shock.	

CTI - Antithrombotics January 2010

Adis Clinical Trials Insight: Ongoing Trials – Status Tracking January 2010

The table below highlights the ongoing trials whose status has changed during January 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700050440	Aspirin Paclitaxel Prasugrel	Recruiting	IV	Paclitaxel + aspirin +/- prasugrel: therapeutic use Prevention of coronary stent thrombosis Post-Approval trial of the Taxus Liberte paclitaxel-eluting coronary stent system	Boston Scientific Corporation, Daiichi Sankyo Inc, Eli Lilly
2 700026947	Atorvastatin Clopidogrel	Active, no longer recruiting	II	Atorvastatin, clopidogrel: pharmacodynamics Effects on the formation of cerebral emboli In patients with Alzheimer's disease or vascular dementia	
3 700047284	Clopidogrel Dexlansoprazole Esomeprazole Lansoprazole Omeprazole	Recruiting	I	Clopidogrel +/- dexlansoprazole, esomeprazole, lansoprazole, omeprazole: pharmacodynamics Effect on steady-state pharmacokinetics and pharmacodynamics of clopidogrel In volunteers	Takeda Global Research and Development Center
4 700050857	Immune-globulin Pentoxifylline	Recruiting	IV	Immune globulin vs pentoxifylline vs immune globulin + pentoxifylline: therapeutic use Sepsis Drugs alone or in combination in patients with neonatal sepsis	
5 700010370	Cilostazol Clopidogrel	Completed	IV	Cilostazol vs clopidogrel: therapeutic use Stroke Phase IV trial in patients with symptomatic intracranial stenosis: TOSS 2 study	Otsuka Pharmaceutical
6 700038023	Aspirin Clopidogrel	Recruiting	II	Aspirin, clopidogrel: therapeutic use Intermittent claudication In patients with peripheral arterial disease stage II	Mego Afek
7 700035729	AVE-5026	Active, no longer recruiting	III	AVE 5026: therapeutic use Prevention of thromboembolism, pulmonary embolism, deep vein thrombosis In patients have undergone hip fracture surgery: SAVE-HIP3 trial	sanofi-aventis
8 700035043	Alteplase Heparin	Active, no longer recruiting	IV	Heparin + alteplase: therapeutic use Deep vein thrombosis Efficacy and cost-effectiveness of catheter-directed thrombolysis	

CTI - Antithrombotics January 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
9 700046022	Enoxaparin-sodium YM-150	Active, no longer recruiting	II/III	YM 150 vs enoxaparin sodium: therapeutic use Prevention of thromboembolism, deep vein thrombosis, pulmonary embolism In patients undergoing total knee replacement surgery	Astellas Pharma
10 700047060	YM-150	Active, no longer recruiting	III	YM 150: therapeutic use Secondary prevention of deep vein thrombosis, pulmonary embolism, thromboembolism	Astellas Pharma
11 700024324	Biolimus-A9 Paclitaxel	Completed	III	Biolimus A9 vs paclitaxel: therapeutic use Prevention of coronary artery restenosis	Terumo
12 700015012	Dalteparin-sodium Ibuprofen	Active, no longer recruiting	IV	Dalteparin sodium vs ibuprofen: therapeutic use Thrombophlebitis In patients with superficial disease	Pfizer
13 700015201	Idrabiotaparinux-sodium Warfarin	Active, no longer recruiting	III	Idrabiotaparinux sodium vs warfarin: therapeutic use Pulmonary embolism The phase III CASSIOPEA trial	sanofi-aventis
14 700042410	Paclitaxel	Active, no longer recruiting	II/III	Paclitaxel: therapeutic use Prevention of coronary artery restenosis Comparing drug eluting balloon vs standard balloon in combination with bare stent and drug eluting stent in patients with complex lesions	
15 700025020	Pioglitazone	Completed	II	Pioglitazone: pharmacodynamics Effect on biomarkers with proven links to future cardiovascular events Phase II trial in patients with peripheral arterial disease and type 2 diabetes mellitus	Wyeth
16 700020139	Sulodexide	Active, no longer recruiting	II	Sulodexide: pharmacodynamics Effects on systemic glycoalyx volume In patients with type 2 diabetes mellitus with or without microalbuminuria: the SUGAR trial	Alfa Wassermann SpA
17 700039083	Argatroban Desirudin	Discontinued	IV	Argatroban vs desirudin: therapeutic use Thrombocytopenia Cost utility trial in patients with heparin-induced disease without clinically evident thrombosis	Canyon Pharmaceuticals
18 700036490	Aspirin	Active, no longer recruiting		Aspirin: pharmacodynamics Effects on changes in pro-angiogenic and anti-angiogenic protein levels In women with breast cancer on tamoxifen therapy	

CTI - Antithrombotics January 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
19 700050468	Caffeine Dextromethorphan Midazolam Omeprazole PLX-4032 Warfarin	Recruiting	I	PLX-4032 + cytochrome P-450 enzyme system modulators: pharmacokinetics Effect on drug concentrations Phase I trial in patients with malignant melanoma	Roche
20 700049058	Aspirin Clopidogrel	Recruiting	III	Aspirin +/- clopidogrel: therapeutic use Stroke, transient ischaemic attacks In high-risk patients with acute non-disabling cerebrovascular event	
21 700037439	Aspirin	Active, no longer recruiting	IV	Aspirin: pharmacodynamics Effects of chronic administration on platelet aggregation and thromboxane levels In high-risk subjects	
22 700035337	Betrixaban Warfarin	Completed	II	Betrixaban vs warfarin: adverse reactions Various toxicities Phase II trial in patients at risk of stroke	Portola Pharmaceuticals
23 700032379	Clopidogrel	Active, no longer recruiting	IV	Clopidogrel: therapeutic use Prevention of coronary artery restenosis	
24 700029911	Idrabioparin sodium Warfarin	Active, no longer recruiting	III	Idrabioparin sodium vs warfarin: therapeutic use Prevention of stroke and thromboembolism In patients with atrial fibrillation: the BOREALIS-AF trial	sanofi-aventis

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.